by Sue Robbins | Aug 29, 2013 | Headache Drugs
A review by Danish researchers has found that after analyzing 20 separate studies that changes in the brain’s white matter and tiny lesions could be found in the brains’ of migraine sufferers. The results were published in the journal Neurology. The reason...
by Sue Robbins | May 20, 2013 | Headache Drugs
The U.S. Food and Drug Administration has approved the first generic versions of Zomig and Zomig-ZMT (orally disintegrating tablets). Zomig is in the class of drugs called triptans, and is indicated for the acute treatment of migraine with or without aura in adults....
by Sue Robbins | Mar 25, 2013 | Headache Drugs
Cephalgia has published an article discussing the 2010 Global Burden of Disease Survey ranking migraine as the 7th highest specific cause of disability globally (based upon ictal disability, i.e. during migraine attack). This is an important recognition for migraine...
by Dr Robbins | Mar 11, 2013 | Headache Drugs
Research recently published in Neurology, the medical journal of the American Academy of Neurology suggests that triggers for migraine with aura may not be as strong as some people believe. The study looked at 27 people with migraine with aura, who identified bright...
by Dr Robbins | Jan 18, 2013 | Headache Drugs
The pharmaceutical company NuPathe Inc. has announced that the FDA has approved Zecuity for the acute treatment of migraine with or without aura in adults. A single-use, battery-powered patch, Zecuity delivers sumatriptan through the skin. The patch provides relief...
